Dual inhibitors of PI3K/mTOR or mTOR-selective inhibitors: Which way shall we go?

Current Medicinal Chemistry

Volumn 18, Issue 36, 2011, Pages 5528-5544

  Sabbah, D A ^a   Brattain, M G ^b   Zhong, H ^c  

^a NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

Author keywords

And cancer; Kinase inhibitors; mTORC1; mTORC2; PI3K ; Rapamycin; Selectivity

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; 2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; AZD 8055; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETP 45658; EVEROLIMUS; GEFITINIB; GNE 477; GNE 493; GSK 2126458; GSK 615; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYRICETIN; NVP BAG 956; NVP BKM 120; OSI 027; PACLITAXEL; PANITUMUMAB; PAZOPANIB; PF 04691502; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PKI 179; PKI 402; PKI 587; PP 242; PP 30; RAPAMYCIN; RIDAFOROLIMUS; STAUROSPORINE; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB; WAY 001; WAY 600; WJD 008; WORTMANNIN; WYE 125132; WYE 354; WYE 687; XL 147; XL 765;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; ASTROCYTOMA CELL; BREAST CANCER; CANCER INHIBITION; CANCER SIZE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; COLON CANCER; DRUG DESIGN; DRUG EFFICACY; DRUG SELECTIVITY; DRUG STRUCTURE; GLIOMA; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; KIDNEY GRAFT REJECTION; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NEUROENDOCRINE TUMOR; OVARY ADENOCARCINOMA; PANCREAS TUMOR; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; TUBEROUS SCLEROSIS;

EID: 84055192519     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711798347298     Document Type: Article

References (133)

1. Vivanco, I.; Sawyers, C.L. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat. Rev. Cancer, 2002, 2, 489-501. (Pubitemid 37328931)
2. Maehama, T.; Dixon, J.E. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol., 1999, 9, 125-128. (Pubitemid 29161437)
3. Garcia, A.; Kim, S.; Bhavaraju, K.; Schoenwaelder, S.M.; Kunapuli, S.P. Role of phosphoinositide 3-kinase beta in platelet aggregation and thromboxane A(2) generation mediated by G(i) signaling pathways. Biochem. J., 2010, 429, 369-377.
4. Wee, S.; Wiederschain, D.; Maira, S.M.; Loo, A.; Miller, C.; deBeaumont, R.; Stegmeier, F.; Yao, Y.M.; Lengauer, C. PTEN-deficient cancers depend on PIK3CB. Proc. Natl. Acad. Sci. U.S.A., 2008, 105, 13057-13062.
5. Jia, S.; Liu, Z.; Zhang, S.; Liu, P.; Zhang, L.; Lee, S.H.; Zhang, J.; Signoretti, S.; Loda, M.; Roberts, T.M.; Zhao J.J. Kinase-dependent and -independent functions of the p110 phosphoinositide-3-kinase in cell growth, metabolic regulation and oncogenic transformation. Nature, 2008, 454, 776-79.
6. Carpintero, R.; Brandt, K.J.; Gruaz, L.; Molnarfi, N.; Lalive, P.H.; Burger, D. Glatiramer acetate triggers PI3K delta/AKT and MEK/ERK pathways to induce IL-1 receptor antagonist in human monocytes. Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 17692-17697.
7. Herman, S.E.M.; Gordon, A.L.; Wagner, A.J.; Heerema, N.A.; Zhao, W.; Flynn, J.M.; Jones, J.; Andritsos, L.; Puri, K.D.; Lannutti, B.J.; Giese, N.A.; Zhang, X.; Wei, L.; Byrd, J.C.; Johnson, A.J. Phosphatidylinositol 3-kinasedelta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood, 2010, 116, 2078-2088.
8. Rueckle, T.; Schwarz, M.K.; Rommel, C. PI3K gamma inhibition: towards an 'aspirin of the 21st century'? Nat. Rev. Drug Discov., 2006, 5, 903-918.
9. Huang, C.; Mandelker, D.; Schmidt-Kittler, O.; Samuels, Y.; Velculescu, V.E.; Kinzler, K.W.; Vogelstein, B.; Gabelli, S.B.; Amzel, L.M. The structure of a human p110 alpha/p85 alpha complex elucidates the effects of oncogenic PI3K alpha mutations. Science, 2007, 318, 1744-1748. (Pubitemid 350274378)
10. Zvelebil, M.J.; Waterfield, M.D.; Shuttleworth, S.J. Structural analysis of PI3-kinase isoforms: Identification of residues enabling selective inhibition by small molecule ATP-competitive inhibitors. Arch. Biochem. Biophys., 2008, 477, 404-410.
11. Frederick, R.; Denny, W.A. Phosphoinositide-3-kinases (PI3Ks): Combined comparative Modeling and 3D-QSAR to rationalize the inhibition of p110 alpha. J. Chem. Inf. Model., 2008, 48, 629-638. (Pubitemid 351535430)
12. Oshiro, N.; Yoshino, K.; Tolcunaga, C.; Hara, K.; Eyuchi, S.; Avruch, J.; Yonezawa, K. Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Cell Struct. Funct., 2004, 29, 83-83.
13. Carracedo, A.; Ma, L.; Teruya-Feldstein, J.; Rojo, F.; Salmena, L.; Alimonti, A.; Egia, A.; Sasaki, A.T.; Thomas, G.; Kozma, S.C.; Papa, A.; Nardella, C.; Cantley, L.C.; Baselga, J.; Pandolfi, P.P. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest., 2008, 118, 3065-3074.
14. Veilleus, A.; Houde, V.P.; Bellmann, K.; Marette, A. Chronic inhibition of the mTORC1/S6K1 pathway increases insulin-induced PI3K activity but inhibits Akt2 and glucose transport stimulation in 3T3-L1 adipocytes. Mol. Endocrinol., 2010, 24, 766-778.
15. Guertin, D.A.; Sabatini, D.M. Defining the role of mTOR in cancer. Cancer Cell, 2007, 12, 9-22. (Pubitemid 47001784)
16. Alessi, D.R.; Andjelkovic, M.; Caudwell, B.; Cron, P.; Morrice, N.; Cohen, P.; Hemmings, B.A. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J., 1996, 15, 6541-6551. (Pubitemid 26413787)
17. Guertin, D.A.; Stevens, D.M.; Thoreen, C.C.; Burds, A.A.; Kalaany, N.Y.; Moffat, J.; Brown, M.; Fitzgerald, K.J.; Sabatini, D.M. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to AKT-FOXO and PKC alpha but not S6K1. Dev. Cell, 2006, 11, 859-871. (Pubitemid 44804279)
18. Sarbassov, D.D.; Ali, S.M.; Sengupta, S.; Sheen, J.H.; Hsu, P.P.; Bagley, A.F.; Markhard, A.L.; Sabatini, D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and AKT/PKB. Mol. Cell, 2006, 22, 159-168.
19. Gutierrez, A.; Snyder, E.L.; Marino-Enriquez, A.; Zhang, Y.X.; Sioletic, S.; Kozakewich, E.; Grebliunaite, R.; Ou, W.B.; Sicinska, E.; Raut, C.P.; Demetri, G.D.; Perez-Atayde, A.R.; Wagner, A.J.; Fletcher, J.A.; Fletcher, C.D.M.; Look, A.T. Aberrant AKT activation drives well-differentiated liposarcoma. Proc. Natl. Acad. Sci. U.S.A., 2011, 108, 16386-16391.
20. Guba, M.; von Breitenbuch, P.; Steinbauer, M.; Koehl, G.; Flegel, S.; Hornung, M.; Bruns, C.J.; Zuelke, C.; Farkas, S.; Anthuber, M.; Jauch, K.W.; Geissler, E.K. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med., 2002, 8, 128-135. (Pubitemid 34155123)
21. Zhou, H.; Luo, Y.; Huang, S. Updates of mTOR inhibitors. Anti-Cancer Agents Med. Chem., 2010, 10, 571-581.
22. Wu, P.; Hu, Y. PI3K/AKT/mTOR pathway inhibitors in cancer: A perspective on clinical progress. Curr. Med. Chem., 2010, 17, 4326-4341.
23. Kong, D.; Yamori, T. Advances in development of phosphatidylinositol 3-kinase inhibitors. Curr. Med. Chem., 2009, 16, 2839-2854.
24. Faivre, S.; Kroemer, G.; Raymond, E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov., 2006, 5, 671-688. (Pubitemid 44151605)
25. Thatcher, N.; Chang, A.; Parikh, P.; Pereira, J.R.; Ciuleanu, T.; von Pawel, J.; Thongprasert, S.; Tan, E.H.; Pemberton, K.; Archer, V.; Carroll, K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 2005, 366, 1527-1537. (Pubitemid 41540110)
26. Cho, B.C.; Im, C.; Park, M.; Kim, S.K.; Chang, J.; Park, J.P.; Choi, H.J.; Kim, Y.J.; Shin, S.; Sohn, J.H.; Kim, H.; Kim, J.H. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J. Clin. Oncol., 2007, 25, 2528-2533. (Pubitemid 47041225)
27. Zhong, H.; Tran, L.M.; Stang, J.L. Induced-fit docking studies of the active and inactive states of protein tyrosine kinases. J. Mol. Graph. Model., 2009, 28, 336-346.
28. Hug, B.; Abbas, R.; Leister, C.; Burns, J.; Sonnichsen, D. A single-dose, crossover, placebo-and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects. Clin. Cancer Res., 2010, 16, 4016-4023.
29. Laheru, D.; Croghan, G.; Bukowski, R.; Rudek, M.; Messersmith, W.; Erlichman, C.; Pelley, R.; Jimeno, A.; Donehower, R.; Boni, J.; Abbas, R.; Martins, P.; Zacharchuk, C.; Hidalgo, M. A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer. Clin. Cancer Res., 2008, 14, 5602-5609.
30. Yap, T.A.; Vidal, L.; Adam, J.; Stephens, P.; Spicer, J.; Shaw, H.; Ang, J.; Temple, G.; Bell, S.; Shahidi, M.; Uttenreuther-Fischer, M.; Stopfer, P.; Futreal, A.; Calvert, H.; de Bono, J.S.; Plummer, R. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J. Clin. Oncol., 2010, 28, 3965-3972.
31. Kelly, R.J.; Carter, C.; Giaccone, G. Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab. J. Clin. Oncol., 2010, 28, e507-510.
32. Xie, H.; Lin, L.P.; Tong, L.J.; Jiang, Y.; Zheng, M.Y.; Chen, Z.; Jiang, X.Y.; Zhang, X.W.; Ren, X.W.; Qu, W.C.; Yang, Y.; Wan, H.; Chen, Y.; Zuo, J.P.; Jiang, H.L.; Geng, M.Y.; Ding, J. AST1306, A novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. PLoS One, 2011, 6(7), e21487.
33. Avizienyte, E.; Ward, R.A.; Garner, A.P. Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations. Biochem. J., 2008, 415, 197-206.
34. Nautiyal, J.; Yu, Y.; Aboukameel, A.; Kanwar, S.S.; Das, J.K.; Du, J.; Patel, B.B.; Sarkar, F.H.; Rishi, A.K.; Mohammad, R.M.; Majumdar, A.P. ErbBinhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells. Mol. Cancer Ther., 2010, 9, 1503-1514.
35. Bonner, J.A.; Harari, P.M.; Giralt, J.; Azarnia, N.; Shin, D.M.; Cohen, R.B.; Jones, C.U.; Sur, R.; Raben, D.; Jassem, J.; Ove, R.; Kies, M.S.; Baselga, J.; Youssoufian, H.; Amellal, N.; Rowinsky, E.K.; Ang, K.K. Radiotherapy plus cetuximab for squamous-cell carcinoma of the Head and Neck. N. Engl. J. Med., 2006, 354, 567-578. (Pubitemid 43209104)
36. Vermorken, J.B.; Mesia, R.; Rivera, F.; Remenar, E.; Kawecki, A.; Rottey, S.; Erfan, J.; Zabolotnyy, D.; Kienzer, H.R.; Cupissol, D.; Peyrade, F.; Benasso, M.; Vynnychenko, I.; De Raucourt, D.; Bokemeyer, C.; Schueler, A.; Amellal, N.; Hitt, R. Platinum-based chemotherapy plus cetuximab in Head and Neck cancer. N. Engl. J. Med., 2008, 359, 1116-1127.
37. Yao, J.C.; Shah, M.H.; Ito, T.; Bohas, C.L.; Wolin, E.M.; Cutsem, E.V.; Hobday, T.J.; Okusaka, T.; Capdevila, J.; de Vries, E.G.E.; Tomassetti, P.; Pavel, M.E.; Hoosen, S.; Haas, T.; Lincy, J.; Lebwohl, D.; Öberg, K. N. Engl. J. Med., 2011, 364, 514-523.
38. Stallone, G.; Schena, A.; Infante, B.; Paolo, S.D.; Loverre, A.; Maggio, G.; Ranieri, E.; Gesualdo, L.; Schena, F.P.; Grandaliano, G. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N. Engl. J. Med., 2005, 352, 1317-1323. (Pubitemid 40411498)
39. Miyazawa, M.; Yasuda, M.; Fujita, M.; Kajiwara, H.; Hirabayashi, K.; Takekoshi, S.; Hirasawa, T.; Murakami, M.; Ogane, N.; Kiguchi, K.; Ishiwata, I.; Mikami, M.; Osamura, R.Y. Therapeutic strategy targeting the mTOR-HIF-1 alpha-VEGF pathway in ovarian clear cell adenocarcinoma. Pathol. Int., 2009, 59, 19-27.
40. Wang, L.; Shi, W.; Wu, Z.; Varna, M.; Wang, A.; Zhou, L.; Chen, L.; Shen, Z.; Lu, H.; Zhao, W.; Janin, A. Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma. J. Hematol. Oncol., 2010, 3, 30.
41. Shah, N.P.; Skaggs, B.J.; Branford, S.; Hughes, T.P.; Nicoll, J.M.; Paquette, R.L.; Sawyers, C.L. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J. Clin. Invest., 2007, 117, 2562-2569. (Pubitemid 47494357)
42. Jaeger-Lansky, A.; Cejka, D.; Ying, L.; Preusser, M.; Hoeflmayer, D.; Fuereder, T.; Koehrer, S.; Wacheck, V. Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo. Cancer Biol. Ther., 2010, 9, 919-927.
43. Clinical Trials: www.clinicaltrials.gov.
44. Walker, E.H.; Pacold, M.E.; Perisic, O.; Stephens, L.; Hawkins, P.T.; Wymann, M.P.; Williams, R.L. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell, 2000, 6, 909-919.
45. Wymann, M.P.; BulgarelliLeva, G.; Zvelebil, M.J.; Pirola, L.; Vanhaesebroeck, B.; Waterfield, M.D.; Panayotou, G. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol. Cell. Biol., 1996, 16, 1722-1733. (Pubitemid 26095645)
46. Vlahos, C.J.; Matter, W.F.; Hui, K.Y.; Brown, R.F. A specific inhibitor of phosphatidylnositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4- one (Ly294002). J. Biol. Chem., 1994, 269, 5241-5248.
47. Sarkar, J.; Singh, N.; Meena, S.; Sinha, S. Staurosporine induces apoptosis in human papillomavirus positive oral cancer cells at G2/M phase by disrupting mitochondrial membrane potential and modulation of cell cytoskeleton. Oral Oncol. 2009, 45, 974-979.
48. Noethlings, U.; Murphy, S.P.; Wilkens, L.R.; Henderson, B.E.; Kolonel, L.N. Flavonols and pancreatic cancer risk -The multiethnic cohort study. Am. J. Epidemiol. 2007, 166, 924-931. (Pubitemid 47511689)
49. Kim, J.; Kwon, J.Y.; Lee, D.E.; Kang, N.J.; Heo, Y.; Lee, K.W.; Lee, H.J. MKK4 is a novel target for the inhibition of tumor necrosis factor-alphainduced vascular endothelial growth factor expression by myricetin. Biochem. Pharmacol., 2009, 77, 412-421.
50. Kim, H.J.; Kim, S.K.; Kim, B.S.; Lee, S.H.; Park, Y.S.; Park, B.K.; Kim, S.J.; Kim, J.; Choi, C.; Kim, J.S.; Cho, S.D.; Jung, J.W.; Roh, K.H.; Kang, K.S.; Jung, J.Y. Apoptotic effect of quercetin on HT-29 colon cancer cells via the AMPK signaling pathway. J. Ag. Food Chem., 2010, 58, 8643-8650.
51. Yaguchi, S.; Fukui, Y.; Koshimizu, K.; Yoshimi, H.; Matsuno, T.; Gouda, H.; Hirono, S.; Yamazaki, K.; Yamori, T. Antitumor activity of ZSTK474, a new phosphatidylitiositol 3-kinase inhibitor. J. Natl. Cancer Inst., 2006, 98, 545-556. (Pubitemid 43898818)
52. Sabbah, D.A.; Vennerstrom, J. L.; Zhong, H. Docking studies on isoformspecific inhibition of phosphoinositide-3-kinases. J. Chem. Inf. Model., 2010, 50, 1887-1898.
53. Hayakawa, M.; Kaizawa, H.; Moritomo, H.; Koizumi, T.; Ohishi, T.; Okada, M.; Ohta, M.; Tsukamoto, S.; Parker, P.; Workman, P.; Waterfield, M. Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110 alpha inhibitors. Bioorg. Med. Chem., 2006, 14, 6847-6858. (Pubitemid 44307656)
54. Hayakawa, M.; Kaizawa, H.; Moritomo, H.; Koizumi, T.; Ohishi, T.; Yamano, M.; Okada, M.; Ohta, M.; Tsukamoto, S.; Raynaud, F.I.; Workman, P.; Waterfield, M.D.; Parker, P. Synthesis and biological evaluation of pyrido[3',2':4,5] furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 2438-2442. (Pubitemid 46507793)
55. Folkes, A.J.; Ahmadi, K.; Alderton, W.K.; Alix, S.; Baker, S.J.; Box, G.; Chuckowree, I.S.; Clarke, P.A.; Depledge, P.; Eccles, S.A.; Friedman, L.S.; Hayes, A.; Hancox, T.C.; Kugendradas, A.; Lensun, L.; Moore, P.; Olivero, A.G.; Pang, J.; Patel, S.; Pergl-Wilson, G.H.; Raynaud, F.I.; Robson, A.; Saghir, N.; Salphati, L.; Sohal, S.; Ultsch, M.H.; Valenti, M.; Wallweber, H.J.A.; Wan, N.C.; Wiesmann, C.; Workman, P.; Zhyvoloup, A.; Zvelebil, M.J.; Shuttleworth, S.J. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1- ylmethyl)-4-morphol in-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem., 2008, 51, 5522-5532.
56. Raynaud, F.I.; Eccles, S.A.; Patel, S.; Alix, S.; Box, G.; Chuckowree, I.; Folkes, A.; Gowan, S.; Brandon, A.D.H.; Di Stefano, F.; Hayes, A.; Henley, A.T.; Lensun, L.; Pergl-Wilson, G.; Robson, A.; Saghir, N.; Zhyvoloup, A.; McDonald, E.; Sheldrake, P.; Shuttleworth, S.; Valenti, M.; Wan, N.C.; Clarke, P.A.; Workman, P. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol. Cancer Ther., 2009, 8, 1725-1738.
57. Link, W.; Oyarzabal, J.; Serelde, B.G.; Albarran, M.I.; Rabal, O.; Cebria, A.; Alfonso, P.; Fominaya, J.; Renner, O.; Peregrina, S.; Soilan, D.; Ceballos, P.A.; Hernandez, A.; Lorenzo, M.; Pevarello, P.; Granda, T.G.; Kurz, G.; Carnero, A.; Bischoff, J.R. Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases. J. Biol. Chem., 2009, 284, 28392-28400.
58. Sutherlin, D.P.; Sampath, D.; Berry, M.; Castanedo, G.; Chang, Z.; Chuckowree, I.; Dotson, J.; Folkes, A.; Friedman, L.; Goldsmith, R.; Heffron, T.; Lee, L.; Lesnick, J.; Lewis, C.; Mathieu, S.; Nonomiya, J.; Olivero, A.; Pang, J.; Prior, W.W.; Salphati, L.; Sideris, S.; Tian, Q.; Tsui, V.; Wan, N.C.; Wang, S.; Wiesmann, C.; Wong, S.; Zhu, B. Discovery of (thienopyrimidin-2-yl) aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer. J. Med. Chem., 2010, 53, 1086-1097.
59. Heffron, T.P.; Berry, M.; Castanedo, G.; Chang, C.; Chuckowree, I.; Dotson, J.; Folkes, A.; Gunzner, J.; Lesnick, J.D.; Lewis, C.; Mathieu, S.; Nonomiya, J.; Olivero, A.; Pang, J.; Peterson, D.; Salphati, L.; Sampath, D.; Sideris, S.; Sutherlin, D.P.; Tsui, V.; Wan, N.C.; Wang, S.; Wong, S.; Zhu, B. Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor. Bioorg. Med. Chem. Lett., 2010, 20, 2408-2411.
60. Dehnhardt, C.M.; Venkatesan, A.M.; Delos Santos, E.; Chen, Z.; Santos, O.; Ayral-Kaloustian, S.; Brooijmans, N.; Mallon, R.; Hollander, I.; Feldberg, L.; Lucas, J.; Chaudhary, I.; Yu, K.; Gibbons, J.; Abraham, R.; Mansour, T.S. Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: Discovery of PKI-402. J. Med. Chem., 2010, 53, 798-810.
61. Mallon, R.; Hollander, I.; Feldberg, L.; Lucas, J.; Soloveva, V.; Venkatesan, A.; Dehnhardt, C.; Delos Santos, E.; Chen, Z.; dos Santos, O.; Ayral-Kaloustian, S.; Gibbons, J. Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor. Mol. Cancer Ther., 2010, 9, 976-984.
62. Raynaud, F.I.; Eccles, S.; Clarke, P.A.; Hayes, A.; Nutley, B.; Alix, S.; Henley, A.; Di-Stefano, F.; Ahmad, Z.; Guillard, S.; Bjerke, L.M.; Kelland, L.; Valenti, M.; Patterson, L.; Gowan, S.; Brandon, A.d.H.; Hayakawa, M.; Kaizawa, H.; Koizumi, T.; Ohishi, T.; Patel, S.; Saghir, N.; Parker, P.; Waterfield, M.; Workman, P. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res., 2007, 67, 5840-5850. (Pubitemid 46985018)
63. Werzowa, J.; Koehrer, S.; Strommer, S.; Cejka, D.; Fuereder, T.; Zebedin, E.; Wacheck, V. Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo. J. Invest. Dermatol., 2011, 131, 495-503.
64. Zou, Z.; Zhang, X.; Wang, F.; Shen, Q.; Xu, J.; Zhang, L.; Xing, W.; Zhuo, R.; Li, D. A novel dual PI3K alpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells. Int. J. Mol. Med., 2009, 24, 97-101.
65. Fan, Q.; Cheng, C.K.; Nicolaides, T.P.; Hackett, C.S.; Knight, Z.A.; Shokat, K.M.; Weiss, W.A. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTENmutant glioma. Cancer Res., 2007, 67, 7960-7965. (Pubitemid 47395125)
66. Kharas, M.G.; Janes, M.R.; Scarfone, V.M.; Lilly, M.B.; Knight, Z.A.; Shokat, K.M.; Fruman, D.A. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL(+) leukemia cells. J. Clin. Invest., 2008, 118, 3038-3050.
67. Park, S.; Chapuis, N.; Bardet, V.; Tamburini, J.; Gallay, N.; Willems, L.; Knight, Z.A.; Shokat, K.M.; Azar, N.; Viguie, F.; Ifrah, N.; Dreyfus, F.; Mayeux, P.; Lacombe, C.; Bouscary, D. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia, 2008, 22, 1698-1706.
68. Chiarini, F.; Fala, F.; Tazzari, P. L.; Ricci, F.; Astolfi, A.; Pession, A.; Pagliaro, P.; McCubrey, J. A.; Martelli, A. M. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-Cell acute lymphoblastic leukemia. Cancer Res., 2009, 69, 3520-3528.
69. Chen, Z.; Venkatesan, A.M.; Dehnhardt, C.M.; Ayral-Kaloustian, S.; Brooijmans, N.; Mallon, R.; Feldberg, L.; Hollander, I.; Lucas, J.; Yu, K.; Kong, F.; Mansour, T.S. Synthesis and SAR of novel 4-morpholinopyrrolopyrimidine derivatives as potent phosphatidylinositol 3-kinase inhibitors. J. Med. Chem., 2010, 53, 3169-3182.
70. Venkatesan, A.M.; Dehnhardt, C.M.; Delos Santos, E.; Chen, Z.; Dos Santos, O.; Ayral-Kaloustian, S.; Khafizova, G.; Brooijmans, N.; Mallon, R.; Hollander, I.; Feldberg, L.; Lucas, J.; Yu, K.; Gibbons, J.; Abraham, R.T.; Chaudhary, I.; Mansour, T.S. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5 '-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J. Med. Chem., 2010, 53, 2636-2645.
71. Venkatesan, A.M.; Chen, Z.; Dos Santos, O.; Dehnhardt, C.; Delos Santos, E.; Ayral-Kaloustian, S.; Mallon, R.; Hollander, I.; Feldberg, L.; Lucas, J.; Yu, K.; Chaudhary, I.; Mansour, T.S. PKI-179: An orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor. Bioorg. Med. Chem. Lett., 2010, 20, 5869-5873.
72. Li, T.; Wang, J.; Wang, X.; Yang, N.; Chen, S.; Tong, L.; Yang, C.; Meng, L.; Ding, J. WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant. J. Pharmacol. Exp. Ther., 2010, 334, 830-838.
73. Aziz, S.A.; Jilaveanu, L.B.; Zito, C.; Camp, R.L.; Rimm, D.L.; Conrad, P.; Kluger, H.M. Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin. Cancer Res., 2010, 16, 6029-6039.
74. Tamburini, J.; Green, A.S.; Bardet, V.; Chapuis, N.; Park, S.; Willems, L.; Uzunov, M.; Ifrah, N.; Dreyfus, F.; Lacombe, C.; Mayeux, P.; Bouscary, D. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood, 2009, 114, 1618-1627.
75. Chapuis, N.; Tamburini, J.; Green, A.S.; Vignon, C.; Bardet, V.; Neyret, A.; Pannetier, M.; Willems, L.; Park, S.; Macone, A.; Maira, S.; Ifrah, N.; Dreyfus, F.; Herault, O.; Lacombe, C.; Mayeux, P.; Bouscary, D. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin. Cancer Res., 2010, 16, 5424-5435.
76. Cho, D.C.; Cohen, M.B.; Panka, D.J.; Collins, M.; Ghebremichael, M.; Atkins, M.B.; Signoretti, S.; Mier, J.W. The efficacy of the novel dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin. Cancer Res., 2010, 16, 3628-3638.
77. Brachmann, S.M.; Hofmann, I.; Schnell, C.; Fritsch, C.; Wee, S.; Lane, H.; Wang, S.; Garcia-Echeverria, C.; Maira, S. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc. Natl. Acad. Sci. U.S.A., 2009, 106, 22299-22304.
78. Konstantinidou, G.; Bey, E.A.; Rabellino, A.; Schuster, K.; Maira, M.S.; Gazdar, A.F.; Amici, A.; Boothman, D.A.; Scaglioni, P.P. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res., 2009, 69, 7644-7652.
79. Liu, T.; Koul, D.; LaFortune, T.; Tiao, N.; Shen, R.J.; Maira, S.; Garcia-Echevrria, C.; Yung, W.K.A. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol. Cancer Ther., 2009, 8, 2204-2210.
80. McMillin, D.W.; Ooi, M.; Delmore, J.; Negri, J.; Hayden, P.; Mitsiades, N.; Jakubikova, J.; Maira, S.; Garcia-Echeverria, C.; Schlossman, R.; Munshi, N.C.; Richardson, P.G.; Anderson, K.C.; Mitsiades, C.S. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res., 2009, 69, 5835-5842.
81. Serra, V.; Markman, B.; Scaltriti, M.; Eichhorn, P.J.A.; Valero, V.; Guzman, M.; Luisa Botero, M.; Llonch, E.; Atzori, F.; Di Cosimo, S.; Maira, M.; Garcia-Echeverria, C.; Lluis Parra, J.; Arribas, J.; Baselga, J. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res., 2008, 68, 8022-8030.
82. Marone, R.; Erhart, D.; Mertz, A.C.; Bohnacker, T.; Schnell, C.; Crniljanovic, V.; Stauffer, F.; Garcia-Echeverria, C.; Giese, B.; Maira, S.; Wymann, M. P. Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. Mol. Cancer Res., 2009, 7, 601-613.
83. Weisberg, E.; Banerji, L.; Wright, R.D.; Barrett, R.; Ray, A.; Moreno, D.; Catley, L.; Jiang, J.; Hall-Meyers, E.; Sauveur-Michel, M.; Stone, R.; Galinsky, I.; Fox, E.; Kung, A.L.; Griffin, J.D. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABLand mutant FLT3-expressing cells. Blood, 2008, 111, 3723-3734.
84. Maira, S.M.; Stauffer, F.; Schnell, C.; García-Echeverría, C. PI3K inhibitors for cancer treatment: where do we stand? Biochem. Soc. Trans., 2009, 37, 265-272.
85. Knight, S.D.; Adams, N.D.; Burgess, J.L.; Chaudhari, A.M.; Darcy, M.G.; Donatelli, C.A.; Luengo, J.I.; Newlander, K.A.; Parrish, C.A.; Ridgers, L.H.; Sarpong, M.A.; Schmidt, S.J.; van Aller, G.S.; Carson, J.D.; Diamond, M.A.; Elkins, P.A.; Gardiner, C.M.; Garver, E.; Gilbert, S.A.; Gontarek, R.R.; Jackson, J.R.; Kershner, K.L.; Luo, L.; Raha, K.; Sherk, C.S.; Sung, C.; Sutton, D.; Tummino, P.J.; Wegrzyn, R.J.; Auger, K.R.; Dhanak, D. Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Med. Chem. Lett., 2010, 1, 39-43.
86. Bowles, D.W.; Jimeno, A. New phosphatidylinositol 3-kinase inhibitors for cancer. Expert Opin. Investig. Drugs., 2011, 20, 507-518.
87. Feldman, M.E.; Apsel, B.; Uotila, A.; Loewith, R.; Knight, Z.A.; Ruggero, D.; Shokat, K.M. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. Plos Biol., 2009, 7(2): e38.
88. Janes, M.R.; Limon, J.J.; So, L.; Chen, J.; Lim, R.J.; Chavez, M.A.; Vu, C.; Lilly, M.B.; Mallya, S.; Ong, S.T.; Konopleva, M.; Martin, M.B.; Ren, P.; Liu, Y.; Rommel, C.; Fruman, D.A. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat. Med., 2010, 16, 205-213.
89. Cheng, H.; Bagrodia, S.; Bailey, S.; Edwards, M.; Hoffman, J.; Hu, Q.; Kania, R.; Knighton, D.R.; Marx, M.A.; Ninkovic, S.; Sun, S.; Zhang, E. Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design. MedChemComm, 2010, 1, 139-144.
90. Niedermeier, M.; Hennessy, B.T.; Knight, Z.A.; Henneberg, M.; Hu, J.; Kurtova, A.V.; Wierda, W.G.; Keating, M.J.; Shokat, K.M.; Burger, J.A. Isoform-selective phosphoinositide 3-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood, 2009, 113, 5549-5557.
91. Gwak, H.; Shingu, T.; Chumbalkar, V.; Hwang, Y.; DeJournett, R.; Latha, K.; Koul, D.; Yung, W.K.A.; Powis, G.; Farrell, N.P.; Boegler, O. Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma. Int. J. Cancer, 2011, 128, 787-796.
92. Brown, J.R.; Auger, K.R. Phylogenomics of phosphoinositide lipid kinases: perspectives on the evolution of second messenger signaling and drug discovery. BMC Evol. Biol., 2011, 11, 4.
93. Vezina, C.; Kudelski, A.; Sehgal, S.N. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. 1975, 28, 721-726.
94. Yatscoff, R. W.; Legatt, D. F.; Kneteman, N. M. Therapeutic Monitoring of Rapamycin -a New Immunosuppressive Drug. Ther. Drug Monit. 1993, 15, 478-482. (Pubitemid 23347236)
95. Grewe, M.; Gansauge, F.; Schmid, R.M.; Adler, G.; Seufferlein, T. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70(s6K) pathway in human pancreatic cancer cells. Cancer Res., 1999, 59, 3581-3587. (Pubitemid 29381856)
96. Morelon, E.; Mamzer-Bruneel, M.F.; Peraldi, M.N.; Kreis, H. Sirolimus: a new promising immunosuppressive drug. Towards a rationale for its use in renal transplantation. Nephrol. Dial. Transplant. 2001, 16, 18-20. (Pubitemid 32051468)
97. Hidalgo, M.; Rowinsky, E.K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene, 2000, 19, 6680-6686. (Pubitemid 32197708)
98. Shi, Y.F.; Frankel, A.; Radvanyi, L.G.; Penn, L.Z.; Miller, R.G.; Mills, G.B. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in-vitro. Cancer Res., 1995, 55, 1982-1988.
99. Humar, R.; Kiefer, F.N.; Berns, H.; Resink, T.J.; Battegay, E.J. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J., 2002, 16, 771-780. (Pubitemid 34615125)
100. Cejka, D.; Preusser, M.; Fuereder, T.; Sieghart, W.; Werzowa, J.; Strommer, S.; Wacheck, V. mTOR Inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo. Anticancer Res., 2008, 28, 3801-3808.
101. Beuvink, I.; Boulay, A.; Fumagalli, S.; Zilbermann, F.; Ruetz, S.; O'Reilly, T.; Natt, F.; Hall, J.; Lane, H.A.; Thomas, G. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell, 2005, 120, 747-759. (Pubitemid 40568794)
102. Ekshyyan, O.; Rong, Y.; Rong, X.; Pattani, K.M.; Abreo, F.; Caldito, G.; Chang, J.K.S.; Arnpil, F.; Glass, J.; Nathan, C.O. Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma. Mol. Cancer Ther., 2009, 8, 2255-2265.
103. Chen, Y.; Smith, M.L.; Sheets, M.; Ballaron, S.; Trevillyan, J.M.; Burke, S.E.; Rosenberg, T.; Henry, C.; Wagner, R.; Bauch, J.; Marsh, K.; Fey, T.A.; Hsieh, G.; Gauvin, D.; Mollison, K. W.; Carter, G.W.; Djuric, S.W. Zotarolimus, a novel Sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression. J. Cardiovasc. Pharmacol., 2007, 49, 228-235. (Pubitemid 46626015)
104. Hartford, C.M.; Desai, A.A.; Janisch, L.; Karrison, T.; Rivera, V.M.; Berk, L.; Loewy, J.W.; Kindler, H.; Stadler, W.M.; Knowles, H.L.; Bedrosian, C.; Ratain, M.J. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin. Cancer Res., 2009, 15, 1428-1434.
105. Mita, M.; Sankhala, K.; Abdel-Karim, I.; Mita, A.; Giles, F. Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin. Invest. Drugs, 2008, 17, 1947-1954.
106. Thoreen, C.C.; Kang, S.A.; Chang, J.W.; Liu, Q.; Zhang, J.; Gao, Y.; Reichling, L.J.; Sim, T.; Sabatini, D.M.; Gray, N.S. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem., 2009, 284, 8023-8032.
107. Liu, Q.; Chang, J.W.; Wang, J.; Kang, S.A.; Thoreen, C.C.; Markhard, A.; Hur, W.; Zhang, J.; Sim, T.; Sabatini, D.M.; Gray, N.S. Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl) benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J. Med. Chem., 2010, 53, 7146-7155.
108. Yu, K.; Toral-Barza, L.; Shi, C.; Zhang, W.G.; Lucas, J.; Shor, B.; Kim, J.; Verheijen, J.; Curran, K.; Malwitz, D.J.; Cole, D.C.; Ellingboe, J.; Ayral-Kaloustian, S.; Mansour, T.S.; Gibbons, J.J.; Abraham, R.T.; Nowak, P.; Zask, A. Biochemical, cellular, and in vivo activity of novel ATPcompetitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res., 2009, 69, 6232-6240.
109. Zask, A.; Verheijen, J.C.; Curran, K.; Kaplan, J.; Richard, D.J.; Nowak, P.; Malwitz, D.J.; Brooijmans, N.; Bard, J.; Svenson, K.; Lucas, J.; Toral-Barza, L.; Zhang, W.; Hollander, I.; Gibbons, J.J.; Abraham, R.R.; Ayral-Kaloustian, S.; Mansour, T.S.; Yu, K. ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines. J. Med. Chem., 2009, 52, 5013-5016.
110. Zask, A.; Kaplan, J.; Verheijen, J.C.; Richard, D.J.; Curran, K.; Brooijmans, N.; Bennett, E.M.; Toral-Barza, L.; Hollander, I.; Ayral-Kaloustian, S.; Yu, K. Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors. J. Med. Chem., 2009, 52, 7942-7945.
111. Curran, K.J.; Verheijen, J.C.; Kaplan, J.; Richard, D.J.; Toral-Barza, L.; Hollander, I.; Lucas, J.; Ayral-Kaloustian, S.; Yu, K.; Zask, A. Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): Optimization of the 1-substituent. Bioorg. Med. Chem. Lett., 2010, 20, 1440-1444.
112. Yu, K.; Shi, C.; Toral-Barza, L.; Lucas, J.; Shor, B.; Kim, J.E.; Zhang, W.; Mahoney, R.; Gaydos, C.; Tardio, L.; Kim, S.K.; Conant, R.; Curran, K.; Kaplan, J.; Verheijen, J.; Ayral-Kaloustian, S.; Mansour, T.S.; Abraham, R.T.; Zask, A.; Gibbons, J.J. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of
113. Chresta, C.M.; Davies, B.R.; Hickson, I.; Harding, T.; Cosulich, S.; Critchlow, S.E.; Vincent, J.P.; Ellston, R.; Jones, D.; Sini, P.; James, D.; Howard, Z.; Dudley, P.; Hughes, G.; Smith, L.; Maguire, S.; Hummersone, M.; Malagu, K.; Menear, K.; Jenkins, R.; Jacobsen, M.; Smith, G.C.M.; Guichard, S.; Pass, M. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res., 2010, 70, 288-298.
114. Altman, J.K.; Sassano, A.; Kaur, S.; Glaser, H.; Kroczynska, B.; Redig, A.J.; Russo, S.; Barr, S.; Platanias, L.C. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res., 2011, 17, 4378-4388.
115. Carayol, N.; Vakana, E.; Sassano, A.; Kaur, S.; Goussetis, D.J.; Glaser, H.; Druker, B.J.; Donato, N.J.; Altman, J.K.; Barr, S.; Platanias, L.C. Critical roles for mTORC2-and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc. Natl. Acad. Sci. U.S.A., 2010, 107, 12469-12474.
116. Falcon, B.L.; Barr, S.; Gokhale, P.C.; Chou, J.; Fogarty, J.; Depeille, P.; Miglarese, M.; Epstein, D.M.; McDonald, D.M. Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res., 2011, 71, 1573-1583.
117. Zask, A.; Verheijen, J.C.; Richard, D.J.; Kaplan, J.; Curran, K.; Toral-Barza, L.; Lucas, J.; Hollander, I.; Yu, K. Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 2644-2647.
118. Richard, D.J.; Verheijen, J.C.; Yu, K.; Zask, A. Triazines incorporating (R)-3-methylmorpholine are potent inhibitors of the mammalian target of rapamycin (mTOR) with selectivity over PI3K alpha. Bioorg. Med. Chem. Lett., 2010, 20, 2654-2657.
119. Tsou, H.R.; MacEwan, G.; Birnberg, G.; Grosu, G.; Bursavich, M.G.; Bard, J.; Brooijmans, N.; Toral-Barza, L.; Hollander, I.; Mansour, T.S.; Ayral-Kaloustian, S.; Yu, K. Discovery and optimization of 2-(4- substitutedpyrrolo[ 2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR). Bioorg. Med. Chem. Lett., 2010, 20, 2321-2325.
120. Tsou, H.; MacEwan, G.; Birnberg, G.; Zhang, N.; Brooijmans, N.; Toral-Barza, L.; Hollander, I.; Ayral-Kaloustian, S.; Yu, K. 4-Substituted-7-azaindoles bearing a ureidobenzofuranone moiety as potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR). Bioorg. Med. Chem. Lett., 2010, 20, 2259-2263.
121. Watanabe, R.; Wei, L.; Huang, J. mTOR signaling, function, novel inhibitors, and therapeutic targets. J. Nucl. Med., 2011, 52, 497-500.
122. Carcía-Echeverría C. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. Bioorg. Med. Chem. Lett., 2010, 20, 4308-4312.
123. Schenone, S.; Brullo, C.; Musumeci, F.; Rado, M.; Botta, M. ATPcompetitive inhibitors of mTOR: an update. Curr. Med. Chem., 2011, 18, 2995-3014.
124. Liu, P.; Cheng, H.; Roberts, T.M.; Zhao, J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov., 2009, 8, 627-644.
125. Breslin, E.M.; White, P.C.; Shore, A.M.; Clement, M.; Brennan, P. LY294002 and rapamycin co-operate to inhibit T-cell proliferation. Br. J. Pharmacol., 2005, 144, 791-800. (Pubitemid 40516119)
126. Gu, Y.Y.; Lindner, J.; Kumar, A.; Yuan, W.P.; Magnuson, M.A. Rictor/mTORC2 is essential for maintaining a balance between beta-cell proliferation and cell size. Diabetes, 2011, 60, 827-837.
127. Jin, N.; Jiang, T.; Rosen, D.M.; Nelkin, B.D.; Ball, D.W. Dual inhibition of mitogen-activated protein kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J. Clin. Endocrinol. Metab., 2009, 94, 4107-4112.
128. Blanco-Aparicio, C.; Collazo, A.M.; Oyarzabal, J.; Leal, J.F.; Albarán, M.I.; Lima, F.R.; Pequeño, B.; Ajenjo, N.; Becerra, M.; Alfonso, P.; Reymundo, M.I.; Palacios, I.; Mateos, G.; Quiñones, H.; Corrionero, A.; Carnero, A.; Pevarello, P.; Lopez, A.R.; Fominaya, J.; Pastor, J.; Bischoff, J.R. Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition. Cancer Lett., 2011, 300, 145-153.
129. Weigelt, B.; Warne, P.H.; Downward, J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to m TOR inhibitory drugs. Oncogene, 2011, 30, 3222-3233.
130. Mazzoletti, M.; Bortolin, F.; Brunelli, L.; Pastorelli, R.; Di Giandomenico, S.; Erba, E.; Ubezio, P.; Broggini, M. Combination of PI3K/mTOR inhibitors: Antitumor activity and molecular correlates. Cancer Res., 2011, 71, 4573-4584.
131. Serra, V.; Scaltriti, M.; Prudkin, L.; Eichhorn, P.J. A.; Ibrahim, Y.H.; Chandarlapaty, S.; Markman, B.; Rodriguez, O.; Guzman, M.; Rodriguez, S.; Gili, M.; Russillo, M.; Parra, J.L.; Singh, S.; Arribas, J.; Rosen, N.; Baselga, J. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene, 2011, 30, 2547-2557.
132. Dan, S.; Okamura, M.; Seki, M.; Yamazaki, K.; Sugita, H.; Okui, M.; Mukai, Y.; Nishimura, H.; Asaka, R.; Nomura, K.; Ishikawa, Y.; Yamori, T. Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in siloco and biological evaluations. Cancer Res., 2010, 70, 4982-4994.
133. Zhong, H.; Bowen, J.P. Recent advances in small molecule inhibitors of VEGFR and EGFR signaling pathways. Curr. Topics Med. Chem., 2011, 11, 1571-1590.